Hua Medicine Ltd.
2.25
HKD
+0.02
(+0.67%)
ISIN
KYG4644K1022
CUSIP
G4644K102
Return %
Stock
S&P 500
1Y
-34.59
14.20
3Y
49.01
81.12
5Y
-46.68
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Li Chen
- Full Time Employees
- 328
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Hua Medicine, Building 2, Lane 36 Shanghai SH China 201203
- IPO Date
- Sep 14, 2018
- Website
- huamedicine.com
- Similar Companies
- Business
- Hua Medicine (Shanghai) Ltd. Hua Medicine (Shanghai) Ltd. (2552.HK) is a China-based innovative biopharmaceutical company principally engaged in the research, development, and commercialization of novel therapies targeting diabetes and related metabolic disorders. Headquartered in Shanghai, China, with additional offices in Beijing, Wuhan, Hong Kong, and the United States, the company was founded in 2010 and listed on the Hong Kong Stock Exchange in 2018. It operates primarily in the domestic Chinese market with expanding international ambitions, focusing on glucokinase activators to restore glucose homeostasis in patients with unmet medical needs. The company's cornerstone product is HuaTangNing (dorzagliatin tablets, HMS5552), an oral glucokinase activator approved by China's National Medical Products Administration (NMPA) on September 30, 2022, for the treatment of type 2 diabetes (T2D) as monotherapy or in combination with metformin; it requires no dose adjustment for patients with chronic kidney disease (CKD) or renal impairment. HuaTangNing acts on glucokinase in pancreatic islets, liver, and other organs to improve beta-cell function, insulin secretion, and glucose-stimulated GLP-1 release, enabling physiological blood glucose regulation. Its pipeline includes fixed-dose combinations such as dorzagliatin-metformin, dorzagliatin-sitagliptin, and dorzagliatin-empagliflozin for T2D; a second-generation once-daily glucokinase activator (HM-002-1005) for T2D and obesity; lower-dose dorzagliatin formulations (25mg and 50mg) for prediabetes prevention, MODY-2, and diabetes remission via the SENSITIZE 3 study in Hong Kong; and exploratory candidates for diabetic kidney disease (DKD), neurodegeneration, drug addiction, and metabolic diseases like frailty and sarcopenia supported by Mendelian randomization genetic data. In recent developments, HuaTangNing achieved its first full year of reimbursement under China's National Reimbursement Drug List (NRDL) in 2024, driving sales revenue to RMB255.9 million (up 234% year-over-year) across approximately 2,700 hospitals with 2.105 million packs sold; the company terminated its exclusive promotion agreement with Bayer Healthcare Company Limited effective January 1, 2025, assuming full commercialization control in mainland China, which propelled sales to 592,000 packs (RMB73.2 million) in the first two months of 2025, a 199% increase over the prior year period. Hua Medicine recruited Lu Yu, a sales executive with over 20 years of diabetes commercialization experience, to lead its internal sales and marketing team; completed a U.S. single-ascending dose study validating HM-002-1005 for once-daily T2D-obesity therapy; advanced dorzagliatin-metformin fixed-dose combination to commercial dosage validation (expected 2025 completion); expanded manufacturing capacity for 2026-2027 demand; monitored safety in 150,000 patients with exemplary pharmacovigilance recognition; and strengthened its global patent portfolio to over 200 granted patents while preparing 2025 registration submissions for Hong Kong and Macau launches. The company maintains a robust cash position of RMB1,139.8 million as of December 31, 2024, supporting R&D, commercialization, and pipeline expansion into Southeast Asia, Belt and Road regions, and obesity markets.
Company News
Hua Medicine (Shanghai) Ltd. (HUMDF) Q2 2026 Earnings Call Transcript